Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Neoleukin Therapeutics, Inc. NLTX
$0.89
+$0.01 (0.83%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
38069751.00000000
-
week52high
1.34
-
week52low
0.38
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.25294100
-
EPS
-1.02000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Piper Sandler | Overweight | Overweight | 02 мар 2022 г. |
| Stifel | Buy | 06 янв 2021 г. | |
| Baird | Outperform | 23 сент 2020 г. | |
| Piper Sandler | Overweight | Overweight | 13 авг 2020 г. |
| Mizuho | Buy | 18 июн 2020 г. | |
| HC Wainwright & Co. | Buy | Buy | 12 сент 2022 г. |
| B of A Securities | Underperform | Buy | 12 сент 2022 г. |
| HC Wainwright & Co. | Neutral | Buy | 16 ноя 2022 г. |
| Stifel | Hold | Buy | 15 ноя 2022 г. |
| Mizuho | Neutral | Buy | 15 ноя 2022 г. |
| Guggenheim | Neutral | Buy | 15 ноя 2022 г. |
| Guggenheim | Neutral | Buy | 03 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Patel Priti | D | 31082 | 14380 | 02 февр 2023 г. |
| Smith Sean Michael | D | 15960 | 3316 | 02 февр 2023 г. |
| Patel Priti | D | 35000 | 35000 | 01 февр 2023 г. |
| Patel Priti | A | 45462 | 35000 | 01 февр 2023 г. |
| Smith Sean Michael | D | 12500 | 12500 | 01 февр 2023 г. |
| Smith Sean Michael | A | 19276 | 12500 | 01 февр 2023 г. |
| Smith Sean Michael | D | 5000 | 5000 | 10 авг 2022 г. |
| Smith Sean Michael | D | 6776 | 1655 | 10 авг 2022 г. |
| Smith Sean Michael | A | 8431 | 5000 | 10 авг 2022 г. |
| Walkey Carl | A | 150000 | 150000 | 02 авг 2022 г. |
Новостная лента
Neoleukin Therapeutics: Strategic Review Play
Seeking Alpha
19 апр 2023 г. в 04:04
Neoleukin Therapeutics: Strategic Review Play
Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan
Zacks Investment Research
10 мар 2023 г. в 12:15
Neoleukin (NLTX) seeks strategic options to maximize shareholder's value. This includes the undertaking of another restructuring plan to reduce 70% of the existing workforce.
Shares of Neoleukin Therapeutics spike after announcing layoffs and potential sale or merger
GeekWire
09 мар 2023 г. в 10:21
Neoleukin Therapeutics is slashing its workforce by about 70% as it seeks “strategic alternatives” for its future, according to a company statement Wednesday.
Neoleukin (NLTX) Stops Development of Lead Drug, Stock Down
Zacks Investment Research
16 ноя 2022 г. в 12:02
Due to discontinuing the development of its lead candidate, Neoleukin (NLTX) has no pipeline candidates in clinical development. Management undertakes restructuring initiatives to curb cash burn.
Neoleukin Therapeutics, Inc. (NLTX) CEO Jonathan Drachman on Q2 2022 Results - Earnings Call Transcript
Seeking Alpha
10 авг 2022 г. в 00:55
Neoleukin Therapeutics, Inc. (NASDAQ:NLTX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Julie Rathbun - Investor Relations Jonathan Drachman - Chief Executive Officer Priti Patel - Chief Medical Officer Sean Smith - Vice President, Finance Conference Call Participants Mary Kate - Bank of America Charles Zhu - Guggenheim Securities Ben Burnett - Stifel Mara Goldstein - Mizuho Securities Operator Good afternoon and thank you for joining us today for the Neoleukin Therapeutics Conference Call. [Operator Instructions] As a reminder, today's conference is being recorded.